Erik J. Blok

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)

Erik J. Blok, Judith R. Kroep, Elma Meershoek‐Klein Kranenbarg et al. · JNCI Journal of the National Cancer Institute · 2017 · 196 citations · Full text

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes

Marcelo Sobral‐Leite, Izhar Salomon, Mark Opdam et al. · Breast Cancer Research · 2019 · 127 citations · Full text

Cytoplasmic Overexpression of HER2: A Key Factor in Colorectal Cancer

Erik J. Blok, Peter J.K. Kuppen, Jeroen EM van Leeuwen et al. · Clinical Medicine Insights Oncology · 2013 · 83 citations · Full text

Mouse Monoclonal Antibody, Breast Oncology, Her2 Expression +14

Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial

Marloes G.M. Derks, Erik J. Blok, Caroline Seynaeve et al. · The Lancet Oncology · 2017 · 55 citations · Full text

Breast Oncology, Oncology, 10-Year Follow-up +12

Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer

Márcia A. Inda, Erik J. Blok, Peter J.K. Kuppen et al. · Molecular Cancer Therapeutics · 2019 · 50 citations · Full text